• Record Q1 MetaXplore test sales of 3,884 in Australia, up 112% vs PCP
• Q1 MetaXplore annualised run-rate of 15,500+ tests sold in Australia, up 112% vs PCP
• Record Q1 MetaXplore test sales of 783 in the UK, up 83% QoQ

Microba Life Sciences Ltd (ASX: MAP) has reported its Q1 FY26 results, highlighting continued strong growth in its core MetaXplore test sales. In Australia, the company recorded 3,884 MetaXplore tests sold in Q1, up 112% compared to the prior corresponding period (PCP). This translated to an annualised run-rate of over 15,500 tests sold, also up 112% vs PCP. The number of ordering clinicians in Australia grew to 837, up 71% vs PCP, supported by consistent clinician engagement, focused field activity, ongoing product enhancements, and increased tests per ordering clinician. In the UK, Microba reported record Q1 MetaXplore test sales of 783, up 83% quarter-on-quarter, with MetaXplore now representing 100% of GI tests sold in the region as the company has discontinued all legacy UK testing products. The company's total Q1 revenue was $3.6 million, down 1% vs PCP, aligned with the strategic discontinuation of legacy product revenue. Excluding legacy products, revenue grew 42% vs PCP. Through disciplined cost management, Microba has also cut operating expenditure by more than 26% in Q1 FY26 versus Q4 FY25, excluding one-off and restructuring items. The company has also released new product features, including 'Practitioner Pays' and 'Admin Accounts', to streamline the ordering process and support the needs of its target healthcare professionals and clinics. Microba is on track to achieve its FY26 regional break-even guidance and strategic objectives, including expanding clinical adoption, achieving break-even in Australia and the UK, and driving strong growth in core test volumes.

FY26 break-even milestones: Based on operating break-even at a regional level (forecasted to be achieved at test volumes of >24,000, split across Australia and the UK). Break-even figures are on a regional EBITDA basis only and exclude Corporate, Product Development Expenditure and Share Based Payments expense.

Microba is building the platform for personalised, microbiome-based healthcare. The company is focused on expanding clinical adoption, achieving break-even in Australia and the UK, driving strong growth in core test volumes, and pursuing initial market penetration in the United States and Europe over the next ~3 years.